Provided by Tiger Fintech (Singapore) Pte. Ltd.

Armata Pharmaceuticals, Inc.

1.45
+0.10007.43%
Volume:12.31K
Turnover:17.99K
Market Cap:52.28M
PE:-1.63
High:1.48
Open:1.44
Low:1.41
Close:1.35
Loading ...

Armata Pharmaceuticals Secures Additional $4.65 Million Non-Dilutive Funding from U.S. Department of Defense to Support Ongoing Clinical Trial of AP-SA02

Reuters
·
Yesterday

Armata Pharmaceuticals Inc - Topline Data Expected Q2 2025 for Future Trial

THOMSON REUTERS
·
Yesterday

Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding From the U.S. Department of Defense to Support Ongoing Disarm Clinical Trial of AP-Sa02

THOMSON REUTERS
·
Yesterday

Press Release: Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Dow Jones
·
Yesterday

New Strong Sell Stocks for April 24th

Zacks
·
24 Apr

New Strong Sell Stocks for April 9th

Zacks
·
09 Apr

Armata Pharmaceuticals Q4 2024 GAAP EPS $(0.23) Beats $(0.35) Estimate, Sales $1.24M Miss $1.56M Estimate

Benzinga
·
21 Mar

BRIEF-Armata Pharmaceuticals Announces Fourth Quarter And Full-Year 2024 Results And Provides Corporate Update

Reuters
·
21 Mar

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update

THOMSON REUTERS
·
21 Mar

Armata Pharmaceuticals Enters $10 Million Secured Credit Agreement with Innoviva

MT Newswires Live
·
13 Mar

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit

PR Newswire
·
11 Mar

Armata Pharmaceuticals Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Dec 2024

Armata Pharma’s inhaled AP-PA02 shows positive results in Phase 2 study

TIPRANKS
·
19 Dec 2024

Armata Pharmaceuticals Announces Encouraging Results From the Phase 2 Tailwind Study of Inhaled AP-Pa02 in Non-Cystic Fibrosis Bronchiectasis Subjects With Chronic Pulmonary Pseudomonas Aeruginosa Infection

THOMSON REUTERS
·
19 Dec 2024

Armata Pharmaceuticals Inc - One Possibly-Related Serious Adverse Event Linked to Acute Pulmonary Event

THOMSON REUTERS
·
19 Dec 2024

Armata Pharmaceuticals Inc - Inhaled AP-Pa02 Well-Tolerated With Mild Adverse Events

THOMSON REUTERS
·
19 Dec 2024

Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

PR Newswire
·
19 Dec 2024

BRIEF-Armata Pharmaceuticals Announces That CEO Dr. Deborah Birx Will Deliver A Presentation At The 5th Annual Phage Futures Annual Meeting

Reuters
·
19 Nov 2024

Armata Pharmaceuticals Announces That CEO DR. Deborah Birx Will Deliver a Presentation at the 5TH Annual Phage Futures Annual Meeting

THOMSON REUTERS
·
19 Nov 2024

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting

PR Newswire
·
19 Nov 2024